Objectives: To assess the long-term efficacy and tolerability of sodium hyaluronate (Hyalgan) after 1 cycle of 5 intra-articular (IA) injections in patients with osteoarthritis (OA) of the knee. The benefits of a second treatment cycle in patients with renewed need for therapy also were examined.
intra-articular (IA) environment (2) . In OA, there is a reduction in both the average molecular weight and the concentration of hyaluronan in the joint, changes that are thought to contribute to the severity of OA pathology (3) . These observations have led to several investigations of the potential beneficial effects of IA hyaluronan injections in patients with OA of the knee (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) .
The product used in this study, Hyalgan (Fidia Pharmaceutical, Padua, Italy), is a highly purified, concentrated viscous solution (20 mg/2 mL) of natural sodium hyaluronate salt extracted from rooster combs, with a molecular weight in the range of 500 to 730 kDa.
Clinical trials comparing Hyalgan with IA placebo injections have generally shown statistically and clinically significant beneficial effects as well as good tolerability (4) (5) (6) (7) . Hyalgan also has been compared with saline in randomized, controlled clinical trials (8) (9) (10) and with a number of other therapies used for the treatment of OA, including oral nonsteroidal anti-inflammatory drugs (8) , IA corticosteroids (11) (12) (13) (14) (15) , superoxide dismutase [Orgotein; manufacturer, city, state (16) ] and mucopolysaccharide polysulphuric acid ester [Arteparon; manufacturer, city, state (17) ].
This study was initially designed to investigate the safety and efficacy of 5 IA injections of Hyalgan in comparison with 10 IA injections of Arteparon in patients with OA of the knee. The study also sought to examine the efficacy and duration of effect of repeated cycles of Hyalgan treatment by using a masked observer design. However, Arteparon was withdrawn from the German and Austrian markets and the study was continued with Hyalgan alone. The data that were collected before the withdrawal of Arteparon were evaluated in an interim analysis. For the main efficacy parameters, pain on movement and joint function, there were statistically significant differences between the 2 groups at the end of treatment in favor of Hyalgan. Moreover, the tolerability of Hyalgan was superior to that of Arteparon (18).
After the withdrawal of Arteparon, the study design was changed from randomized, singleblind, parallel group to open-label. The initial objectives were maintained, namely (1) to determine the efficacy and safety of Hyalgan; (2) to determine the onset of effect of Hyalgan therapy; (3) to determine the duration of the efficacy of 1 treatment cycle of 5 injections of Hyalgan; and (4) to gain experience regarding efficacy, sustained efficacy, and safety with repeated treatment cycles. An abbreviated symposium report of the results of the open-label study presented here has been published previously (19) .
PATIENTS AND METHODS

Demographics
There were 108 patients enrolled in the openlabel study at 14 Austrian rheumatologic and orthopedic centers. Thirty-seven patients who were included in the initial comparative, controlled study were treated with Hyalgan and remained in the study after the design was changed. An additional 71 patients were recruited after the change in study design. Of the total study population, 77 patients were women (71%) and 31 were men (29%). Patients ranged in age from 23 to 75 years, with a mean age of 57.7 Ϯ 10.6 years (all mean values represented as Ϯ SD). The mean age for men was 53.0 Ϯ 10.2 years, and the mean age for women was 59.5 Ϯ 10.2 years; mean body weight was 80.1 Ϯ 13.7 kg.
Patients were eligible for inclusion in the study if they had OA of the knee with a radiographic severity of 1, 2, or 3 according to the Kellgren and Lawrence criteria (20) , subjective complaints for at least 1 year, knee pain for at least 20 days in the month before the study start, and a minimum score for pain on movement of at least 3.3 cm on a 10-cm Visual Analogue Scale (VAS) (21) .
In 52 patients (48%), both knees were affected by OA. In patients with unilateral OA, the right knee was affected in 37 patients (34%) and the left knee was affected in 19 patients (18%). Hyalgan was administered to the right knee in 66 patients (61%), and to the left knee in the remaining 42 patients (39%). Based on radiographic examination, severity of disease was assessed by stage by using the Kellgren and Lawrence criteria: the possibility of osteophytes was found in 26 patients (24%), stage 1; presence of osteophytes was detected in 41 patients (38%), stage 2; and multiple osteophytes and narrowing of the femorotibial space were identified in another 41 patients (38%), stage 3.
Study Design
Intra-articular injections of Hyalgan were administered at baseline and then once weekly for 4 consecutive weeks for a total of 5 injections. The course of therapy ended after the last injection. Efficacy and safety were recorded at the time of each injection, 1 week after the last injection (which was day 35 after the first injection) and then monthly for up to 12 months after the end of the course of therapy (month 1 through 12). Patients who had a favorable initial response to therapy but whose pain had returned within the 12-month follow-up period, but not before 4 months after the first injection, could request and receive a second course of 5 injections of Hyalgan. These patients were followed up for 1 more year after the end of the second treatment cycle at 2-month intervals. Patients requesting a second course of treatment before 4 months after the first injection of Hyalgan were considered therapeutic failures and were not re-treated. Throughout the study, acetaminophen was allowed up to a maximum daily dose of 2 g as an escape medication for pain.
Efficacy Measures
The primary efficacy parameter was pain intensity on movement, which was measured on a VAS (10-cm line; 0 ϭ no pain to 10 ϭ worst imaginable pain). Secondary parameters included pain intensity on movement and at rest assessed on a 5-point Likert ordinal pain scale (0 ϭ no pain to 4 ϭ very severe pain), and pain at rest (VAS) as well as knee joint function was assessed according to the Larson Total Score (sum of scores for gait [0 to 10] and activity [0 to 40]; total score of 0 ϭ worst to 50 ϭ best) (22) . Other clinical parameters, including onset of effect, maximum walking time (MWT), and global assessment of efficacy scored by the investigator and the patient, consumption of acetaminophen, and signs of inflammation also were evaluated. Onset of effect was defined as the first visit at which the patient showed an improvement over baseline in pain on movement of Ͼ20% by using the VAS, or a 1-category improvement by using the ordinal rating scale. The MWT was determined from patients' estimates of walking time without pain (in 15-minute intervals). The overall assessment of efficacy was expressed by the investigator and by patients at day 35 (1 week after the last injection) in the first and the second treatment cycle (if applicable), and at the end of the follow-up. A standard question was used to determine the change in clinical symptoms: symptom free, markedly improved, slightly improved, unchanged, and deteriorated. Clinical evaluations were made at days 0, 7, 14, 21, 28, and 35 (day 0, day 7, and so on), and then monthly for up to 12 months (month 1 through month 12). For patients receiving a second treatment cycle, follow-up evaluations were made every 2 months for 12 more months after day 35.
Safety and Tolerability
Safety was assessed by laboratory measurements such as erythrocyte sedimentation rate, differential blood count, platelets, prothrombin time, serum alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, creatinine level, and uric acid level. Measurements were performed at baseline, at the end of the first treatment cycle, and at the end of the 12-month follow-up. If applicable, they were assessed at the start and at the end of the second treatment cycle, and again at the end of the 12-month follow-up period of the second treatment cycle. Adverse events were recorded at every examination by spontaneous report of the patient and by oral questioning by the investigator. The severity of each event was rated as "slight," "moderate," or "severe," and the relationship of Hyalgan to the adverse event was designated as "none," "unclear," "possible," or "related."
Statistical Methods
The efficacy parameters were examined for all data available up to the end of the first and the second follow-up periods. In addition, an end-point analysis of the intent-to-treat (ITT) patients was undertaken using the latest result recorded (last observation carried forward [LOCF] ). The mean changes from baseline of the efficacy parameters were analyzed by using the Student t test for paired comparison. No adjustments for multiple comparisons were applied. Throughout this report, mean values are reported as Ϯ standard deviation.
RESULTS
Patients Completing the Study (Completed Patients)
The flow of study participants is presented in Table 1 . Of 108 patients who initiated Hyalgan therapy, 107 (99%) patients finished the first treatment course and 101 (94%) patients attended the visit on day 35. A total of 59 (55%) patients completed the protocol with a single course of treatment and 12 months of follow-up. Fourteen patients completed a repeat course of therapy between 4 and 9 months after their first IA injection of Hyalgan. Six of these patients (43%) completed the second 12 months of posttreatment follow-up and the remaining 8 patients were lost to followup.
A total of 34 patients (32%) did not complete the study through month 12 of follow-up after the first treatment cycle nor did they receive a second course of therapy. Note that the mean baseline values for the second course of treatment include those for 1 patient who enrolled in the study but did not complete the second course of injections.
For these 35 patients, the reasons for discontinuation from the study were the following: adverse events (4 patients), noncompliance (2), patient refusal (10), lost to follow-up (11), protocol violation (5), and other reasons (3).
EFFICACY
Single Course of Therapy
Results for the primary efficacy parameter pain on movement (VAS) and for the secondary efficacy parameters of pain on movement (ordinal scale), pain at rest, Larson score, and MWT showed statistically significant changes from baseline starting at the visit on day 35 (1 week after the last injection). Table 2 shows the mean values and standard deviations for these efficacy parameters for all completed patients (N ϭ 59) and all ITT patients (N ϭ 108) by using the LOCF.
Pain on movement. The mean VAS values for the primary efficacy parameter of pain on movement for all completed patients (N ϭ 59) continuously and significantly decreased through the 12 months of follow-up visits (P Ͻ .01; Table 2 ). The evaluation at month 12 showed an improvement of 72 Ϯ 25% versus baseline. Analyses of the ITT patients' mean VAS scores also showed statistically significant reductions from baseline pain at day 35, month 6 and month 12 of follow-up (P Ͻ 0.01; Table 2 ). At month 12, a mean improvement of 49 Ϯ 44% (P Ͻ .01) was calculated from the mean VAS score by using the LOCF.
One week after the last Hyalgan injection (day 35), 10% of completed patients had no pain (a VAS score of 0); this increased to 25% of patients at the end of 12 months of follow-up. Further, 46 patients showed significant improvement at day 35. Among the 108 ITT patients, 18% had no pain at their last observation (LOCF) during the first year follow-up period. The change in pain on movement at their last observation compared with baseline was greater than 20% in 73% of patients.
Pain on movement by ordinal scale. Assessment of pain on movement by using a 5-point Likert ordinal scale (0 ϭ best to 4 ϭ worst) showed that 97% of completed patients and 74% of ITT patients reported improvement at month 12 (Table 3) .
Pain at rest. VAS values for pain at rest in the 59 patients who completed the study showed statistically significant decreases from baseline through to follow-up at month 12 (Table 2) , when an improvement of 53% was reported. Of the completed patients, no pain at rest was reported in 67% (39 of 58) of patients on day 35, and 66% (39 of 59) of patients at month 12. Among the ITT patients (using LOCF), VAS values for pain at rest decreased significantly from baseline on day 35 and at month 12 (P Ͻ .01; Table 2 ). Using LOCF, no pain at rest was reported in 54% of patients (58 of 108) on day 35, and 48% of patients (52 of 108) at month 12. Pain at rest by ordinal scale. Using the Likert ordinal scale, 68% of 59 completed patients and 49% of 108 ITT patients rated their pain at rest as improving over 12 months after their first Hyalgan treatment cycle.
Larson Score. The Larson Total Score showed statistically significant improvements from baseline for completed and ITT patients starting on day 35 through the 12-month follow-up (Table 2) . At the end of the 12 months of follow-up, the mean total scores for completed (N ϭ 59) and ITT patients (N ϭ 108) significantly improved from baseline by 35% and 23%, respectively (P Ͻ .01). In addition, the Larson subscores of gait and activity also showed statistically significant increases from baseline for both completed and ITT patients (data not shown).
MWT. At baseline, the MWT for the ITT patients ranged from 10 to 330 minutes (mean, 53.7 Ϯ 47.3 minutes) and that for the completed patients ranged from 15 to 180 minutes (mean, 50.2 Ϯ 35.1 minutes) ( Table 2) . By month 12, MWT had increased to 102.0 Ϯ 54.0 minutes for both the completed and the ITT (without LOCF) patients, representing increases of 103% and 90%, respectively.
Onset of effect. Among those patients completing the 12-month follow-up and achieving a significant clinical improvement in pain on movement, 38% (20 of 52) exhibited improvement 1 week after a single injection of Hyalgan, and 85% (44 of 52) had an improvement as early as 1 week after the third injection of Hyalgan (Table 4) . Similar results were seen with the ITT patients. When the criteria for positive clinical outcomes were compared between the VAS pain assessment and the ordinal scale, there was close agreement in the percentages of patients with improvement. For the ITT patients at day 35 (N ϭ 104), 82% and 83% showed an improvement in pain assessed by NOTE. N ϭ 108, intent-to-treat; N ϭ 59, completed patients. *Pain expressed as the mean visual analog scale Ϯ standard deviation at rest or on movement (VAS, 10-cm line; 0 ϭ no pain to 10 ϭ worst imaginable pain). †Larson Total Score is a measure of the patients' functional score of the OA of the knee, expressed as the mean total score Ϯ standard deviation. ‡MWT is the maximum time in 15-minute intervals that a patients can continuously walk, expressed as mean Ϯ standard variation. §ITT patients include all patients enrolled and receiving a course of therapy.
Completed patients received a full course of 5 injections of Hyalgan and were able to be followed up for the full 12 months of the study. ¶Numbers of patients attending the indicated visit. #Statistically significant, P Ͻ 0.01 by Student t test compared with baseline. **The t test for statistical significance was not analyzed. † †Data were analyzed using the LOCF method for each patient up to day 35 (1 week after the last injection). ‡ ‡Data were analyzed using the LOCF for each patient up to month 12 (end of study).
the VAS and ordinal scales, respectively. Similar results were obtained for the completed patients at day 35 (N ϭ 58), with 88% and 93% showing an improvement in pain assessed by VAS and by the ordinal scales, respectively. This effect lasted through month 12 of follow-up in more than 90% of the patients who completed the study (Table 3) .
Global assessment of efficacy. Both the patients' and physicians' global assessments of overall efficacy showed very favorable results 1 week after the last injection of the first course of treatment (day 35). Of the completed patients, 75% were assessed by the investigator as symptom free or markedly improved, and 22% were assessed as slightly improved. According to the completed patients' self-assessment, 78% were symptom free or markedly improved, and 17% had slight improvement. Among the ITT patients, the investigator assessed 66% of patients as symptom free or markedly improved, 21% as slightly improved, and 6% as unchanged; only 1 patient (1%) was assessed as deteriorated. The ITT patients' self-evaluations were similar; 71% were symptom free or markedly improved, 15% were slightly improved, and 7% were unchanged (Table 5) .
Second course of therapy. Of the 108 included patients, 14 received a second cycle of 5 Hyalgan injections because of a renewed need for therapy *Intent-to-treat patients include all patients enrolled and receiving a course of therapy. Data were analyzed by using the LOCF method for each patient not completing the study. †Completed patients received a full course of 5 injections of Hyalgan, and were followed up for the subsequent 12 months. ‡Only 57 completed patients had an ordinal scale value at day 35, (that is, 93% of the 57 patients improved, which is 92% of all 59 completed patient) §Patients' assessment of knee pain based on an ordinal scale of no to severe pain (0 -4). Improved or worsened designation required a ranking score change of at least 1 category.
The total number of patients and percent of total are represented for all data points. NOTE. Values are shown as n (%). *Days since the first injection of Hyalgan. †The onset of effect using VAS was defined as the first visit at which the patient showed an improvement over baseline VAS score of Ͼ20% for pain on movement. ‡The onset of effect using the ordinal scale was defined as the first visit at which the patient reported an improvement of 1 or more categories for pain on movement.
according to the inclusion criteria of pain on movement (Ͼ3.3 cm on VAS) after 4 months. Nine of these patients were lost to follow-up. The mean time to initiation of the second cycle after baseline of the first cycle was 183 days (approximately 6 months), and the range was 126 to 249 days (approximately 4 to 9 months). Table 6 summarizes the efficacy parameters of pain on movement, pain at rest, Larson Total Score, and MWT for the patients receiving a second course of Hyalgan. All of these efficacy parameters showed improvement over the second course of treatment and follow-up periods.
Safety and Tolerability
The overall safety and tolerability of the Hyalgan treatments were judged by the investigators to be good to very good in 99 (92%) of the ITT patients (N ϭ 108), and moderate in 3 patients (3%), at the end of the first treatment cycle. Similar tolerability was observed by using the patients' evaluations (91% and 3%, respectively).
Fifty (46%) of 108 ITT patients experienced 119 adverse events, of which 13 were recurrent episodes of the same event. The most frequently reported adverse events were back pain (17%) and local manifestations described as injection site reaction (12%) or injection site pain (7%). Of the 119 adverse events, 102 (86%) were rated as only slight or moderate in severity, and 75 (63%) adverse events were reported as not related to the study drug.
Seventeen (14% of total) adverse events in 15 patients were rated as severe. Nine of these events (53%) were judged as not related to the study drug, and 6 events (35%) were judged as possibly related. Only 2 (12%) of the severe adverse events were judged to be related to the study drug: 1 patient developed knee joint effusion and the other patient had a skin eruption on the upper part of the body with pruritus. In both cases, the conditions resolved and the patients did not discontinue the study because of these events. Only 1 adverse event (coronary stenosis) was considered lifethreatening; this event was reported as not related to the study drug. Four patients withdrew from the study because of adverse events. Three of these patients had adverse events rated as severe, but judged not to be related to the study drug. Two of these patients withdrew after accidental falls and 1 withdrew because of coronary stenosis requiring surgery. A fourth patient withdrew as the result of a severe effusion of the knee joint, which was judged as possibly related to the study drug.
No clinically relevant changes in laboratory parameters were noted. There were no withdrawals from the study because of laboratory adverse events.
DISCUSSION
In the present study, 1 treatment cycle with 5 consecutive weekly IA injections of Hyalgan resulted in significant improvements in all efficacy parameters (pain on movement and pain at rest assessed by VAS, Larson Total Score, and MWT) among baseline and subsequent assessments up to month 12 of follow-up in patients with OA of the knee. A therapeutic effect was observed in more than one third of patients as early as 1 week after the first injection, and by day 35, more than 80% of the patients in both patient populations (ITT and completed) reported improvement. For the patients who received a second course of therapy, the mean VAS score for pain on day 35 (N ϭ 14) decreased by 22% from baseline, and decreased by 46% by the end of the 12-month follow-up (N ϭ 6).
Hyalgan was well tolerated in this study: overall safety and tolerability were judged by the investigators to be good to very good in more than 90% of both patient populations (ITT and completed). Of the 4 patients who withdrew from the study because of adverse events, Hyalgan was judged as possibly related in only 1 patient (effusion of the knee joint); the other 3 events were judged as not related to Hyalgan.
This investigation was originally intended to be a randomized, single-blind study comparing the efficacy and tolerability of Hyalgan and Arteparon. However, because of the withdrawal of Arteparon from the Austrian market, the protocol was changed to an open-label assessment of the efficacy and tolerability of Hyalgan. Clearly, the lack of controls limits the conclusions that can be drawn from the results of this study. Moreover, 35 of the enrolled 108 patients did not complete the study to month 12 of follow-up after the first treatment nor did they receive a second course of therapy. Notwithstanding these limitations, the results of this study corroborate those from placebo-controlled trials that showed clinically significant efficacy of Hyalgan in relieving pain associated with OA of the knee for up to 6 months (8, 10) . Importantly, the present study found that approximately two thirds of the patients who completed the study received up to 12 months of pain relief with a single course of Hyalgan, making it highly unlikely that this clinical benefit has any relationship to a placebo effect. Moreover, in patients who initially responded favorably to the first course of Hyalgan therapy for 4 to 9 months, and subsequently completed a second course of therapy, a 46% improvement in their average VAS score for pain on movement was observed at the 12-month followup. Although these long-term clinical benefits seen with Hyalgan treatment are encouraging, they require confirmation in well-controlled studies. Nevertheless, in the management of a chronic and progressive disease such as OA, long-term pain relief to the extent reported here with Hyalgan, coupled with a good tolerability and safety profile, represent important attributes for pharmacologic intervention in this patient population.
Currently, there is a limited repertoire of effective pharmacologic interventions for the management of pain associated with OA. Simple analgesics, opioids, and nonsteroidal anti-inflammatory drugs (including the cyclooxygenase-2 selective inhibitors) all have significant limitations with respect to efficacy, duration of effect, patient acceptability, safety, and tolerability (23, 24) . There is now a significant body of clinical data supporting the beneficial effects of hyaluronans (8, 10, 12, 17) . Although some clinical studies have failed to show a significant clinical benefit of hyaluronans over saline control (25, 26) , they showed significant improvements from baseline measures after hyaluronan therapy. Taken together, the results of this study and those of previous studies support a valuable role for Hyalgan among the available treatment options for patients with pain associated with OA of the knee.
